Poster Viewing Sessions

Poster Viewing Sessions are organised on Monday 15, Tuesday 16, Wednesday 17 and Thursday 18 November.

During those sessions, Young investigators will reply live and by chat to questions moderated by the session chairs following the broadcasting of their video recorded poster presentation via the live stream.

Hour Location	Title	Location
15:30	Poster Viewing Session I - Basic Studies Hans Lassmann Ariel Miller
15:30	ID 4: Mitochondria in pathophysiology of innate immunity in multiple sclerosis Mr João Marcos Brandet
15:35	ID 6: Serum CXCL13 Levels Associate with EDSS Score and Spinal Cord Lesion Number in MS Dr Ezgi Vural
15:40	ID 15: Improving Motor Evoked Potential as preclinical marker of cortico-spinal conduction Dr Valerio Castoldi
15:45	ID 19: Apathy and cognitive dysfunctions in Multiple Sclerosis: a 4-year follow-up study Dr Simona Raimo
15:50	ID 22: Visual and motor evoked potentials in experimental autoimmune encephalomyelitis Ms Elena Rossi
15:55	ID 23: In vivo assessment of optic chiasm associated with Hespretin in demyelination model Ms Saeideh Baradaran
16:00	ID 55: When MS doesn't give another chance: about 3 aggressive cases Dr Houyam Tibar
16:05	ID 61: CD138+ Plasma cells but not CD20+ B cells exhibit cytotoxic behavior in MS patients Dr. Vinicius Boldrini
16:10	ID 62: CSF signature of cytotoxic T cells and MS-like lesions in a patient after COVID-19 Dr. Vinicius Boldrini
16:15	ID 66: Microglial-axon contacts at the Node of Ranvier in Multiple Sclerosis and EAE Dr Vasiliki Pantazou
16:20	ID 70: Fluoxetine modulates macrophages-induced Th17-immune response in multiple sclerosis Dr Mikhail Melnikov
16:25	ID 71: Anti-Ganglioside Antibodies in Guillain-Barre Syndrome a novel panel essay Mrs Yuanyuan Zhang
16:30	ID 72: Difference of cognitive impairment mode between HSP and MS Dr Jin Bi
16:35	ID 73: Histological characterisation of staged lesion topography in the MS spinal cord Mr Alex Waldman
16:40	ID 76: Dimethyl and monomethyl fumarate, and cannabidiol effects in neurons and microglia Ms Alicia Sánchez Sanz

Hour Location	Title	Location
15:30	Poster Viewing Session II - Clinical Gilles Edan Prof Edgardo Cristiano
15:30	ID 5: Peripheral neuropathy as potential side effect of teriflunomide Dr Serena Borrelli
15:35	ID 11: Sodium/potassium ratio as a conversion predictor from CIS to MS Dr Marlene Arbeu-Reyes
15:40	ID 14: Quantify upper limb impairment in the ADL in people with Multiple Sclerosis Dr Marco Pisa
15:45	ID 25: CONFIDENCE: Real-world effectiveness of ocrelizumab in relapsing MS over 18 months Dr Julius Eggebrecht
15:50	ID 28: Exercise therapy as supplemental treatment in early multiple sclerosis: a RCT Dr Morten Riemenschneider
15:55	ID 32: Humoral immune response to SARS-CoV2 vaccines in multiple sclerosis and controls Prof Dr Gabriel Bsteh
16:00	ID 40: Prevalence of PTSD in Russian population of MS patients Mr Ivan Kalinin
16:05	ID 41: Quality of life and fear of disease progression in MS patients with PTSD Ms Mariia Andreeva
16:10	ID 49: Frequency of New Silent MRI lesions in MOGAD and AQP4-NMOSD Dr Valentina Camera
16:15	ID 65: The impact of COVID-19 on patients with neuromyelitis optica beyond infection risk Dr Hexiang Yin
16:20	ID 77: Long-term disability outcomes in multiple sclerosis: a 25-year follow-up study Dr Sena Destan Bunul

Hour Location	Title	Location
15:30	Poster Viewing Session III - Epidemiology Prof. Dr Per Soelberg Sørensen Prof. Dr Maria Trojano
15:30	ID 9: The disease-modifying drugs for multiple sclerosis and association with survival Dr Huah Shin Ng
15:35	ID 12: Low socioeconomic status is associated with a higher mortality risk in MS Dr Floriane Calocer
15:40	ID 16: Multiple sclerosis disease-modifying drug use in immigrants vs long-term residents Dr Jonas Graf
15:45	ID 17: Effects of vitamin D and body mass index on relapse hazard in multiple sclerosis Ms Marijne Vandebergh
15:50	ID 27: Genetic and clinical risk factors for spasticity among people with MS Ms Kelsi Smith
15:55	ID 31: SOCIOECONOMIC STATUS AND ACCESS TO MS TREATMENT IN A COLOMBIAN COHORT Dr Adriana Casallas Vanegas
16:00	ID 33: MS polygenic risk is not associated with white matter integrity in UK Biobank Dr Cameron Watson
16:05	ID 63: A LONGITUDINAL STUDY OF THE PSYCHOLOGICAL WELL-BEING AFTER A DIAGNOSIS OF MS Dr Gloria Dalla Costa

Hour Location	Title	Location
15:30	Poster Viewing Session IV - Investigations & Treatment Hans-Peter Hartung Prof. Dr Oscar Fernández
15:30	ID 26: An imaging signature in choroid plexuses in pre-symptomatic multiple sclerosis Dr Vito Ricigliano
15:35	ID 29: Functional brain states predict cognitive decline 5 years after a CIS Dr Ismail Koubiyr
15:40	ID 34: Retinal thinning predicts relapse remission in relapsing multiple sclerosis Prof Dr Gabriel Bsteh
15:45	ID 48: Resting-state and structural MRI metrics related to fatigue in MS, MOGAD and NMOSD Dr Valentina Camera
15:50	ID 54: Natalizumab extended-interval dosing is associated with subtle inflammatory changes Dr Marco Pisa
15:55	ID 64: Visual pathway damage evolution in multiple sclerosis related acute optic neuritis Dr Simone Guerrieri
16:00	ID 68: USPIO-SWI showed vascular factors involved in "black holes" in multiple sclerosis Dr Li-Jie Zhang
16:05	ID 74: Clinical and genetic features of MS in the Republic of Bashkortostan Dr Timur Galiulin
16:10	ID 75: Humoral immune response to COVID-19 Vaccines in patients with MS on different DMTs Dr Alexandra Akrivaki
16:15	ID 39: TDCS to prevent optic nerve damage and to promote remyelination in EAE mouse model Dr Silvia Marenna
16:20	ID 46: Systemic corticosteroid therapy and visual outcome of ischemic optic neuropathy Dr Sofia Bezerra de Oliveira Costa
16:25	ID 53: Characterisation of the immune system after ocrelizumab treatment in MS Mrs Lien Beckers